Skip to main content
Premium Trial:

Request an Annual Quote

Genstruct Partners with Pfizer on Preclinical Drug Analysis

NEW YORK (GenomeWeb News) – Informatics company Genstruct said today it will collaborate with Pfizer on current and future preclinical drug safety studies.
 
Under a new master research agreement, Genstruct will initially work with Pfizer on a systems biology analysis of the biological mechanisms that underlie drug-induced liver injury.
 
Genstruct President and CEO Keith Elliston said the company has previously worked with Pfizer on oncology, vascular injury, cardiovascular, and metabolic disease.
 
Genstruct focuses on integrating and analyzing large-scale data from transcriptomic, proteomic, metabolomic, and phosphoproteomic research, Elliston said. The firm also applies its technologies to finding biomarkers of efficacy and toxicity of drugs.
 
Financial terms of the agreement were not released, but Genstruct said that it retains biomarker intellectual property rights.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.